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a b s t r a c t
Bone metastases represent common long term complications of patients with breast cancer. Zoledronic
acid, an amino-bisphosphonate and mevalonate pathway inhibitor, is an established agent for the
treatment of bone metastases. Direct antitumor effects of zoledronic acid have been proposed in breast
cancer. Statins are another group of mevalonate pathway inhibitors that have been repeatedly discussed
for potential anti-tumor activity. In this study, we tested the hypothesis, whether these agents regulate
adhesion of breast cancer cells to extracellular matrix components. Treatment of breast cancer cells with
zoledronic acid and atorvastatin, signiﬁcantly impaired MDA-MB-231 breast cancer cell adhesion on the
αvβ3 ligands gelatin and vitronectin, but had no effect on collagen type 1 (α2β1-ligand) and ﬁbronectin
(α5β1-ligand). Anti-adhesive effects of zoledronic acid were fully reversed by geranylgeranyl pyropho-
sphate (GGPP), but not by farnesylpyrophosphate (FPP). Furthermore, effects of zoledronic acid and
atorvastatin were mimicked by a speciﬁc inhibitor of geranylgeranylation GGTI-298. Functional (using
integrin array) and quantitative (using FACS) integrin analyses on MDA-231 cells following zoledronic
acid exposure revealed decreased levels of αv and αvβ3 expression. In addition to its effects on integrin
mediated adhesion of breast cancer cells, the presence of zoledronic acid caused pronounced
morphological changes in MDA-231 cells as seen by F-actin and vinculin rearrangement. Furthermore,
phosphorylation of the focal adhesion kinase was inhibited by zoledronic acid. In both cases, changes
were fully reversed by GGPP. These results emphasize the role of mevalonate pathway mediated
impairment of geranylgeranylation in the anti-adhesive effects of zoledronic acid in breast cancer cells.
& 2014 Elsevier GmbH. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
Breast cancer is the most prevalent malignancy in women, and
the occurrence of bone metastases is a common long-term
complication of this disease [1]. The pathophysiology of bone
metastases is complex and a number of steps have to be surpassed
by the cancer cell to successfully establish a metastatic lesion,
including the adhesion of cancer cells at their metastatic site [2].
Bisphosphonates represent a standard therapy for patients with
malignant bone lesions [3]. In addition to their established
anti-resorptive effects, direct effects of amino-bisphosphonates
on tumor biology have been proposed [4]. Established in vitro and
in vivo effects of bisphosphonates on cancer cells include an
induction of apoptosis, inhibition of proliferation, migration and
invasion as well as anti-angiogenic effects [4–6]. In contrast to ﬁrst
generation bisphosphonates, which act by forming toxic ATP
analogs, amino-bisphosphonates are inhibitors of the mevalonate
pathway that block the farnesyl pyrophosphate (FPP) synthase [7].
FPP synthase inhibition leads to a decreased formation of iso-
prenoid lipids such as FPP and geranylgeranyl pyrophosphate
(GGPP) and thereby impairs posttranslational protein prenylation
[8]. In fact, many of the observed anti-tumor effects of bispho-
sphonates have been proposed to be mediated by inhibited protein
geranylgeranylation [9]. Statins are the second major class of
clinically approved compounds that act by mevalonate pathway
inhibition [10]. Statins are widely used for their cholesterol-lowering
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effects, but have also been associated with potential direct anticancer
effects [11].
Cancer cell adhesion is an important step of the metastatic
cascade that is essential for the cancer to establish persistence at
the site of metastasis. Mevalonate pathway inhibition may impair
the adhesive abilities of circulating cancer cells and thereby impact
their metastatic potential. Indeed, anti-adhesive effects of bispho-
sphonates have been described for several cell types, including
breast cancer and HUVEC [12,13], but the underlying molecular
mechanisms have not been studied in detail. In this study we
investigate the effects of zoledronic acid on integrin mediated
adhesion of breast cancer cells in the context of mevalonate
pathway inhibition.
2. Materials and methods
2.1. Cells and reagents
Human MDA-MB-231 breast cancer cells were purchased from
ATCC (Manassas, VA). MDA-BONE cells (also known as MB-231-
TxSA) were obtained from the University of Texas (San Antonio, USA).
All cell lines were cultured in DMEM/Ham's F-12 (PAA, Pasching,
Austria) with 10% fetal calf serum supreme (Lonza, Cologne, Germany)
and 1% penicillin/streptomycin (PAA, Pasching, Austria). Cell line
authenticity was determined by short tandem repeat proﬁling and
by matching with the known proﬁles at DSMZ (German Collection of
Microorganisms and Cell Cultures). Zoledronic acid, atorvastatin,
mevalonate, geranylgeranyl-pyrophosphate (GGPP), farnesyl pyropho-
sphate (FPP), GGTI-298 and FTI-277 were obtained from Sigma-
Aldrich (Munich, Germany). Zoledronic acid was solved in PBS.
Mevalonate, FPP and GGPP were solved in methanol:NH4OH
solution and atorvastatin, GGTI-298 and FTI-277 were solved in
DMSO. Appropriate controls were added to untreated control cells.
Breast cancer cell lines were treated with zoledronic acid, atorvas-
tatin, FTI-277 and GGTI-298 for 24 h (unless otherwise indicated).
Mevalonate substrates (GGPP, FPP and mevalonate) were supple-
mented 2 h prior to zoledronic acid treatment to reverse speciﬁc
pathway inhibition.
2.2. Western blot
Western blot analyses were performed as previously described
[14]. Brieﬂy, cells were washed and scraped in a lysis buffer and
quantiﬁed. Twenty mg of protein were loaded on a SDS–PAGE and
transferred onto a 0.2 mm nitrocellulose membrane. Following
blocking for 1 h with 5% non-fat dry milk in Tris-buffered saline
with 1% tween-20 (TBS-T), membranes were incubated with the
primary antibody overnight. After washing, the membrane was
incubated for 1 h with the HRP-conjugated secondary antibody.
Membranes were washed 3 times with TBS-T again, and proteins
were visualized with Super Signal (Pierce, Bonn, Germany) enhanced
chemiluminescence. Antibody for RAP1A (sc-1482) was from Santa
Cruz (Heidelberg, Germany) and the RAS (610001) antibody was
from BD Biosciences (Heidelberg, Germany). Antibodies for FAK
and phosphoFAK (Tyr397) were from Cell Signaling Technology
(Boston, USA).
2.3. Adhesion assay
The adhesion assay was performed using 96-well microplates
coated with vitronectin (R&D Systems, Wiesbaden, Germany),
gelatin, collagen or ﬁbronectin (all from BD, Heidelberg, Germany).
The microplates were rehydrated with 200 μl PBS/well for 30 min
at room temperature prior to use and the PBS removed before
adding the cells. MDA-231 breast cancer cells were treated with
different inhibitors of the mevalonate pathway for 24 h as indi-
cated. Cells were then stained with the ﬂuorescent dye DilC12(3)
(from BD Biosciences, Heidelberg, Germany) for 1 h and washed
twice with PBS. DilC12(3) is a ﬂuorescent tracer speciﬁcally
designed to label viable cells for tumor cell invasion or migration
assays. After carefully harvesting the cells with 0.0015 M EDTA/
PBS, they were washed again with PBS, counted and reconstituted
in DMEM. Cells (125,000/well) were then given on 96-well
microplates coated with different surfaces and incubated at 37 1C
for 1 h in a CO2 incubator allowing them to adhere. Afterwards the
plates were washed gently 3 times with PBS to remove non
adherent cells and 100 μl of DMEM added into the wells. The
adherent cells were then quantiﬁed by their relative ﬂuorescence
signal with Fluostar Omega plate reader at 544/590 nm.
2.4. Integrin array
We used the Alpha/Beta (α/β) Integrin-Mediated Cell Adhesion
Array Combo Kit (Chemicon/Merck Millipore, Schwalbach,
Germany) to examine the adhesion of MDA-231 breast cancer
cells in relation to their cell surface integrin subunit expression.
This assay contains microplates coated with monoclonal antibo-
dies against the human integrins α1–α5, αv, αvβ3, β1–β4, β6, αvβ5
and α5β1. The attachment to the different integrin subunits is used
as an indirect indicator to assess functioning integrin cell surface
expression. MDA-231 breast cancer cells were treated as indicated
and harvested with 0.0015 M EDTA/PBS, counted and diluted
separately to the ﬁnal concentration of 1106 cells/ml. Thereafter,
100 ml of the cell suspension was added to each of the anti-integrin
coated wells and the control wells and incubated for 1 h at 37 1C.
After incubation the wells were washed gently twice with assay
buffer. Next, 150 ml of assay buffer and 50 ml of Lysis Buffer/Dye
solution provided in the kit were adjoined to each well and
incubated for 15 min at room temperature. Finally, 150 ml of the
mixture were transferred to a 96-well plate and absorbance was
determined with a Fluostar Omega plate reader at 485/530 nm.
2.5. Immunoﬂuorescence
Immunoﬂuorescence (IF) was performed as previously
described [15]. Brieﬂy, MDA-231 cells were disseminated on glass
slides and treated with zoledronic acid, atorvastatin, GGTI-298,
FTI-277 and GGPP as indicated. After washing the cells with PBS,
they were ﬁxed for 15 min with 4% paraformaldehyde/PBS and
permeabilized after a triple washing step with PBS for 20 min
using 0.1% Triton X-100/PBS. Afterwards they were washed again
with PBS. Cells were then blocked with 1% BSA, 0.05% Tween/PBS
for 1 h. After a triple washing step with PBS, 200 μl of 10 μg/ml
Alexa-Fluor-488-Phalloidin (from Cell Signaling Technology,
Boston, USA) and 2.5 μg/ml Vinculin (from Sigma-Aldrich, Munich,
Germany) in 1% BSA, 0.05% Tween/PBS were added per well and
incubated for 1 h at room temperature. Afterwards the cells were
washed again three times with PBS and incubated for 1 h at room
temperature with Alexa-Fluor-594 antibody (from Life Techno-
logies, Darmstadt, Germany). Following a brief washing step with
PBS, the cells were stained with 0.2 μg/ml DAPI for 5 min and then
washed several times. The ﬂuorescence-preserving mounting
medium Dako was added to the slides to assess the cells thereafter
using digital microscopy.
2.6. Flow cytometry
MDA-231 breast cancer cells were treated with zoledronic acid
for 24 h, harvested with 0.0015 M EDTA/PBS and resuspended in
FACS buffer (1% BSA/PBS). Cells were stained with an αvβ3-FITC
antibody or with an αv (CD51) antibody (both from Chemicon/
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Merck Millipore, Schwalbach, Germany) for 1 h. The αv antibody
was consecutively stained with Alexa Fluor 488 antibody (from
Life Technologies, Darmstadt, Germany) for 1 h after a washing
step with FACS buffer. After washing the cells three times they
were resuspended in FACS buffer and analyzed with a FACSCalibur
ﬂow cytometer following a standard protocol.
2.7. Statistical analyses
Results are presented as means7standard deviation (SD). All
experiments were repeated at least three times. Statistical evalua-
tions were performed using a one-way ANOVA or a Student's
T-test. P valueso0.05 were considered statistically signiﬁcant.
3. Results
3.1. Zoledronic acid and atorvastatin reduce breast cancer adhesion
to the αvβ3 ligands gelatin and vitronectin
To assess the effects of mevalonate pathway inhibition on
breast cancer cell adhesion, MDA-231 cells were pre-treated with
increasing concentrations of zoledronic acid or atorvastatin for
24 h prior to the adhesion assay on gelatin. Both agents resulted
in a dose dependent inhibition of adhesion, with stronger effects
in atorvastatin treated cells (Fig. 1A and B). Effective mevalonate
pathway inhibition was proven by assessment of immunoblotting
of Rap1A (antibody detects only ungeranylated RAP1A) and RAS
(second band indicates unfarnesylated RAS) (Fig. 1C).
To further clarify the role of integrins in these anti-adhesive
effects, adhesion assays of zoledronic acid and atorvastatin treated
MDA-231 cells were repeated on different extracellular matrix
components. Reductions in adhesion on vitronectin, another αvβ3-
ligand, were comparable to those seen on gelatin. Treatment with
zoledronic acid reduced adhesion by 69% and atorvastatin reduced
adhesion by 45% (po0.01). However, zoledronic acid and atorvas-
tatin had no effects on collagen type 1 (α2β1-ligand) and ﬁbronectin
(α5β1-ligand) (Fig. 2). MDA-Bone cells, a highly osteotropic MDA-
231 subclone, showed an even greater reduction in adhesion to
gelatin upon exposure to mevalonate pathway inhibitors (Fig. 4A).
3.2. Anti-adhesive effects of zoledronic acid and atorvastatin are
mediated by inhibition of geranylgeranylation
The role of the mevalonate pathway in this observed effect was
speciﬁed by treating MDA-231 cells with speciﬁc inhibitors of
farnesylation (FTI-277) and geranylgeranylation (GGTI-298). GGTI-
298 caused a strong reduction of adhesion on gelatin (po0.001)
and vitronectin (po0.05), but had no effects on collagen type 1.
Inhibition of farnesylation only had modest effects on MDA-231
adhesion on both gelatin and vitronectin (Fig. 3A). Furthermore,
the anti-adhesive effect of zoledronic acid on gelatin could be
completely reversed by supplementing geranylgeranyl pyropho-
sphate. Other mevalonate pathway metabolites such as mevalo-
nate and farnesyl pyrophosphate did not restore the effects of
zoledronic acid (Fig. 3B). These results emphasize the dominant
role of impaired geranylgeranylation for the observed anti-
adhesive effects. Of note, both FTI-277 and GGTI-298 strongly
reduced the adhesion of MDA-Bone cells (Fig. 4B). The effect of
zoledronic acid was signiﬁcantly, although not fully reversed by
GGPP (Fig. 4C).
3.3. Integrin array
To test whether bisphosphonates have an effect on integrin
function, cell surface integrins were analyzed using an α/β
integrin-mediated cell adhesion kit. Baseline adhesion to different
antibodies varied greatly, indicating differences in integrin expres-
sion (Fig. 5A). Adhesion to α4, β3 and β6 was marginal. On the
other hand there was a strong attachment to α2, α3, αv, αvβ3, β1,
β2, β4, αvβ5 and α5β1 indicating a strong surface expression on
MDA-231 cancer cells. After exposure to zoledronic acid the
expression of αv and αvβ3 decreased signiﬁcantly by 40% and
34%, respectively (po0.05). Of note, adhesion to integrin α5,
which showed a lower baseline expression than αv and αvβ3,
was also signiﬁcantly reduced. Other integrins were not signiﬁ-
cantly affected by treatment with zoledronic acid (Fig. 5A). Expres-
sion of αv and αvβ3 on MDA-231 cells was further assessed by ﬂow
cytometry. In both cases the number of positively labeled cells
signiﬁcantly decreased by 23% and 25%, respectively (po0.05)
(Fig. 5B). The effect of zoledronic acid on the expression of αv and
αvβ3 was largely reversed by the addition of GGPP (Fig. 6A).
Atorvastatin also reduced the adhesion of MDA-231 cells to αv
and αvβ3 integrins by 54% and 56% (po0.01) (Fig. 6B).
3.4. Modiﬁcation of focal adhesion kinase (FAK) and cell morphology
Zoledronic acid and atorvastatin resulted in profound morpho-
logical changes in the cytoskeleton of MDA-231 as assessed by
immunoﬂuorescence staining of vinculin and f-actin. After 24 h
of exposure to mevalonate pathway inhibitors, MDA-231 cells
developed a pronounced spindle-like morphological appearance.
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Fig. 1. Zoledronic acid and atorvastatin dose-dependently reduce breast cancer adhesion. ((A) and (B)) MDA-231 breast cancer cells were treated with zoledronic acid (1–
100 mM) and atorvastatin (1–100 mM) for 24 h. Data are presented as the percentage adhesion on gelatin relative to control treated (PBS, DMSO) cells, and are mean7SD of
3 independent experiments. (C) Inhibition of mevalonate pathway was veriﬁed by assessment of RAS (arrow indicates unfarnesylated band) and ungeranylated RAP1A.
GAPDH served as loading control. *po0.05; **po0.01; ***po0.001.
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These changes were fully compensated when supplementing
GGPP (Fig. 7A).
We next assessed the impact of zoledronic acid on focal
adhesion kinase (FAK) and cell morphology. Exposure to zoledro-
nic acid reduced the phosphorylation of FAK in MDA-231 cells.
Again, this effect was directly mediated by inhibited geranylger-
anylation, as it was mimicked by atorvastatin and GGTI-298 and
completely restored when co-incubated with GGPP (Fig. 7B).
Treatment with FTI-277 did not inﬂuence pFAK.
4. Discussion
The adhesion of disseminated cancer cells to their target
structure is an essential step of the metastatic process. Both
bisphosphonates and statins have been discussed for their direct
anti-tumor effects [16,17]. Here, we assessed the inﬂuence of
zoledronic acid and atorvastatin on the adhesion of two
ER-negative breast cancer cell lines to extracellular matrix pro-
teins. While these agents are primarily used for divergent indica-
tions, namely anti-resorptive therapy and cholesterol reduction,
they have a common target by inhibiting the mevalonate pathway
and a considerable overlap regarding preclinical anti-tumor activ-
ity has been noted [5,18]. Anti-adhesive effects of bisphosphonates
in breast cancer have been previously described [19], but the role
of the mevalonate pathway in this context has not been described
in detail. Prenylation processes are important for the biological
activity of numerous cellular signal transduction proteins. By
blocking the mevalonate pathway both statins and nitrogen-
containing bisphosphonates impair farnesylation and geranyla-
tion. In this study, we show that the observed anti-adhesive effects
of bisphosphonates are directly mediated by an inhibition of
post-translational geranylgeranylation as the effects are fully
reversed in the presence of GGPP, which restores geranylgeranyla-
tion. Furthermore, the speciﬁc inhibition of geranylation using
GGTI-298 has similar effects as zoledronic acid, whereas inhibition
of farnesylation has no effects. This is in line with a number of
previous studies, which have described most anti-tumor effects of
bisphosphonates to be mediated by an inhibited geranylgeranyla-
tion rather than an inhibition of farnesylation [20]. In combination
with the previously described anti-angiogenic effects of zoledronic
acid [14], these anti-adhesive effects may negatively inﬂuence the
metastatic potential of breast cancer cells. Of note, effects were
greater in the highly osteotropic MDA-Bone cells, indicating a
potential higher sensitivity in breast cancer cells with a higher
metastatic risk.
Cell adhesion to extracellular matrix requires the interaction of
different molecules like selectins, cadherins and integrins [21].
Especially αvβ3 integrin has been proposed to mediate the adhe-
sion of malignant cells in different entities such as multiple
myeloma and breast cancer [22,23]. Upon exposure to mevalonate
pathway inhibitors we observed an impaired adhesion of breast
cancer cells that was exclusive to αvβ3 ligands. Consequently,
decreased αvβ3 expression was conﬁrmed with two different
methods. In HUVEC decreased cell surface levels of αvβ3 and
αvβ5 following treatment with zoledronic acid have been pre-
viously reported [24] and these effects have been linked to an
inhibition of prenylation dependent pathways [12].
This study did not investigate the impact of mevalonate path-
way inhibition on the adhesion of estrogen receptor negative
breast cancer cells, which is a study limitation. Furthermore, the
limiting factor of translating preclinical anti-tumor effects of
zoledronic acid are the high concentrations required to achieve
these results. Concentrations between 10 to 100 mM are commonly
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Fig. 2. Zoledronic acid (A) and atorvastatin (B) decrease adhesion of breast cancer cells on αvβ3 ligands. Treatment with zoledronic acid (100 mM) or atorvastatin (10 mM) for
24 h reduces adhesion of MDA-231 breast cancer cells on gelatin and vitronectin (αvβ3-ligands) but not on collagen-I and ﬁbronectin. Data are presented as the relative
adhesion relative to control treated (PBS, DMSO) cells, and are mean7SD of 3–4 independent experiments. *po0.05; **po0.01; ***po0.001.
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required in vitro to achieve consistent effects and although these
concentrations may theoretically accumulate in the bone, they are
certainly not reached in serum where bisphosphonate concentra-
tions decline rapidly (within hours) following infusion. In this
study zoledronic acid concentrations of 10 mM were required to
yield a robust cellular response. Interestingly, considerably lower
concentrations of atorvastatin were needed to achieve comparable
results. Although statins are not established agents in the treatment of
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cancer, there is increasing evidence that statins may have tumor
modulating activity in vitro [25] and in vivo [26,27]. Furthermore,
some observational studies have shown a reduction in cancer-
related mortality by statins [28]. Atorvastatin potently suppressed
the adhesion of breast cancer cells in this study supporting the
potential anti-cancer effects of statins. The higher potency of
statins compared to bisphosphonates may have clinical implica-
tions as the high concentrations of zoledronic acid required to
achieve similar results may limits its translational potential.
In summary, our results demonstrate that mevalonate pathway
inhibition by bisphosphonates and statins exerts anti-adhesive
activity on breast cancer cells by impairing αv and αvβ3 expressions.
This effect is mediated by inhibited geranylgeranylation and warrants
further research on the anti-tumor effects of mevalonate pathway
inhibitors including statins which displayed a higher potency in this
study than zoledronic acid.
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Fig. 6. Atorvastatin decreases the expression of αv and αvβ3 and zoledronic acid impairs integrin expression via inhibited geranylgeranylation. (A) MDA-231 cells were
treated with GGPP (100 mM) 2 h prior to zoledronic acid (100 mM) or zoledronic acid alone and adhesion to the integrins αv and αvβ3 was assessed afterwards. (B) The
adhesion of MDA-231 cells to the integrins αv and αvβ3 was analyzed after treatment with Atorvastatin (10 mM) for 24 h. Atorvastatin reduced the expression of both
integrins signiﬁcantly. Data are presented as the percentage adhesion relative to control treated cells, and are mean7SD of 3–4 independent experiments. *po0.05;
**po0.01; ***po0.001.
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